1. Home
  2. DAVA vs RZLT Comparison

DAVA vs RZLT Comparison

Compare DAVA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$5.31

Market Cap

365.7M

Sector

Technology

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.28

Market Cap

326.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAVA
RZLT
Founded
2000
2010
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.7M
326.4M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
DAVA
RZLT
Price
$5.31
$3.28
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$14.57
$9.17
AVG Volume (30 Days)
528.3K
2.4M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.32
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.26
N/A
P/E Ratio
$20.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.38
$1.07
52 Week High
$23.71
$11.46

Technical Indicators

Market Signals
Indicator
DAVA
RZLT
Relative Strength Index (RSI) 49.49 48.78
Support Level $4.85 $2.80
Resistance Level $7.04 $4.21
Average True Range (ATR) 0.39 0.32
MACD 0.06 -0.01
Stochastic Oscillator 67.52 29.74

Price Performance

Historical Comparison
DAVA
RZLT

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: